Body iron indices at week 4 after tIO treatment and miR-122 overexpression in hepatocytes
| . | IA . | IO . | IO + rAAV . | IO + rAAV-122 . |
|---|---|---|---|---|
| Serum iron, μM | 20.8 ± 5.7** | 42.2 ± 7.7 | 42.0 ± 6.7 | 36.9 ± 4.9 |
| TIBC, μmol/L | 49.7 ± 2.5** | 53.5 ± 4.4 | 54.4 ± 3.8 | 52.5 ± 4.9 |
| TS, % | 41.5 ± 9.6** | 78.3 ± 9.6 | 76.8 ± 8.0 | 70.4 ± 9.0 |
| Liver iron, μg/g | 101.3 ± 47.6** | 1760 ± 273 | 1792 ± 435 | 1665 ± 138 |
| . | IA . | IO . | IO + rAAV . | IO + rAAV-122 . |
|---|---|---|---|---|
| Serum iron, μM | 20.8 ± 5.7** | 42.2 ± 7.7 | 42.0 ± 6.7 | 36.9 ± 4.9 |
| TIBC, μmol/L | 49.7 ± 2.5** | 53.5 ± 4.4 | 54.4 ± 3.8 | 52.5 ± 4.9 |
| TS, % | 41.5 ± 9.6** | 78.3 ± 9.6 | 76.8 ± 8.0 | 70.4 ± 9.0 |
| Liver iron, μg/g | 101.3 ± 47.6** | 1760 ± 273 | 1792 ± 435 | 1665 ± 138 |
Data are presented as mean ± SD (N = 6).
TIBC, total iron-binding capacity; TS, transferrin saturation.
**P < .01 vs IO.